HK Stock Market Move | QYUNS-B(02509) rose by over 6%, the company's operational efficiency has significantly improved, and it is expected that Selexin's sales revenue will reach 300 million yuan by 2025.

QYUNS-B (02509) rose by more than 6%, rising by 6.02% to 8.8 Hong Kong dollars with a trading volume of 2.2807 million Hong Kong dollars as of the time of publication. In terms of news, QX Biotech achieved a revenue of 159 million yuan in 2024; the net loss narrowed by 32.92% year-on-year. The company had previously stated in its 2024 performance meeting that its Silexin as a biosimilar drug has automatically entered the medical insurance catalogue. Combined with Huadong Medicine's strong sales capabilities, it is expected that the sales of this product will reach 300 million yuan in 2025, with a peak of 1.5-2 billion yuan. After the product generates sales profits, the share obtained by QX Biotech will be included in the company's income. In addition, QX Biotech pointed out that it has already established a deep layout with differentiated advantages in the field of skin diseases. Looking ahead, the company will accelerate the upgrade of the 2.0 pipeline strategy with a global innovative perspective, focusing on the treatment of respiratory diseases and inflammatory bowel disease (IBD). These two areas currently have significant unmet clinical needs, and existing therapies are relatively lacking in efficacy, providing greater potential for the company to create the best in class (BIC) or first in class (FIC) products globally, and also presenting a major opportunity for the company to participate in global innovation competition. For multiple innovative products in the respiratory and IBD areas, the company is currently in deep discussions with overseas partners and expects progress in international cooperation within the year. Promoting the internationalization of innovative products is one of the company's important strategic goals this year.